Search PubMed⌕ Search

Biomedical subjects

B I Lord

Publications and source records attributed to B I Lord.

At least 37 records · Page 2Linked to original sources

Feedback inhibitors in normal and tumor tissues.

Negative feedback represents the principal mechanism for regulating growth in biological systems. Over the past 20 years, our understanding of the role played by inhibitory factors governing this process has advanced considerably. This is particularly well illustrated in the field of experimental hematology with the recognition of hemopoietic progenitor cell proliferation inhibitors, an expanding group of unrelated peptides that act to limit proliferation in hemopoietic precursor cells. The characterization and subsequent production of these molecules by chemical synthesis or recombinant DNA technology has enabled investigators to explore their role in normal hemopoiesis and define a potential role in clinical medicine. A number of inhibitory factors, including macrophage inflammatory protein-1 alpha (MIP-1 alpha) and the tetrapeptide AcSDKP appear to share a relative specificity to hemopoietic progenitor cell subsets. Others, such as interferon and tumor necrosis factor, have a more complex action and their hemopoietic effects are likely to be indirect and nonspecific. In addition to the role of inhibitors in normal steady state, it has become increasingly evident that loss of sensitivity to the normal feedback inhibitory signals may be of central importance in carcinogenesis and tumor promotion. This presumably represents a developmental strategy that allows the neoplastic cell to maintain a growth advantage over its normal cell counterpart. The underlying mechanisms that terminate in inhibitor-resistance are yet to be elucidated, but in some instances they may be associated with aberrant tumor suppressor gene function.

Amino Acid Sequence↗

BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation.

Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is an inhibitor of stem cell proliferation affording protection against damage from agents that express their cytotoxicity specifically in the DNA synthesis phase of the cell cycle. Its ability also to modify the self-renewal capacity of the regenerating cells is now shown to improve and maintain haemopoietic recovery following therapy (sublethal irradiation) whose cytotoxic damage is not limited solely to the DNA-S phase of this cycle. Such non-cell cycle-active cytotoxic agents are used clinically in repeated treatment regimens, which are often limited or terminated because of accumulating haemopoietic damage. BB-10010, a non-aggregating variant of MIP-1 alpha, was administered as a continuous dose (1600 micrograms kg-1 24 h-1) via a subcutaneously implanted pump over a period of 7 days. A dose of 4.5 Gy total-body gamma-rays was given 3-4 h after implantation. Day 8 and 12 spleen colony-forming units (CFU-S) were assayed on days 1, 7 and 14 after irradiation. This cycle of treatment was repeated four times (total 56 days), and on day 14 of the last two cycles the marrow-repopulating ability (MRA) was also measured. In the control bone marrow (no BB-10010) CFU-S fell to < 1% of normal within 1 day of irradiation and recovered to 40% at 14 days. Repeated treatments increased the level of damage, and after four cycles CFU-S recovered to only 10% of normal. BB-10010 afforded little benefit in the first treatment cycle, but by the end of the fourth cycle CFU-S still recovered to 35% of normal. MRA was reduced to 7% of normal by the irradiation protocol-about half that maintained by BB-10010 protection. We conclude that BB-10010 (MIP-1 alpha) reduces the degree of accumulated haemopoietic stem cell damage following repeated non-cell cycle-specific cytotoxic insults-a principle which should be valuable in repeated clinical cytotoxic therapy regimens.

Animals↗

The relative spatial distribution of in vitro-CFCs in the bone marrow, responding to specific growth factors.

Haemopoietic progenitor cells are stimulated by a range of growth factors which promote colony growth in culture. The progenitors are a part of an age-structured developmental hierarchy in the tissue. The growth factors, although overlapping in their effects, stimulate cells preferentially at different stages in this programme. Femoral bone marrow was fractionated into axial (close to the central venous sinus) and marginal (close to the bone surface) cells. Progenitors which responded to IL-3, GM-CSF, G-CSF, M-CSF and SCF were then assayed in soft agar cultures. Consequent plots of their spatial distributions showed that the more primitive cells in vitro (responding to IL-3) were concentrated close to the bone surface. The peak concentrations of cells responding primarily to growth factors with progressively more affinity to more mature progenitor cells correspondingly appeared progressively further from the bone surface and closer to the point of release at the central venous sinus. This suggests that the developmental/maturational process in haemopoiesis is accompanied by a progressive movement of cells from the bone surface towards the central axial regions of the bone cavities. The most primitive cells are however exposed, close to the centre of the cavity, by a combination of SCF and G-CSF (or by a 50-fold increase in G-CSF concentration alone). These results corroborate earlier data which indicate a developmental movement of cells from the centre of the marrow tissue towards the bone surface and back again, sequentially encountering a series of growth factors which promote their differentiation into mature cells, for release at the central venous sinus.

Animals↗

Gamma-ray-induced cell killing and chromosome abnormalities in the bone marrow of p53-deficient mice.

Resistance to the lethal effects of ionizing radiation has been demonstrated in a wide variety of cell types with defects in the p53 gene (thymocytes, splenic B and T cells, in vitro hemopoietic colony-forming cells and intestinal cells of the mouse, embryo cells of the rat, and human Burkitt's lymphoma cells). In contrast, Slichenmeyer et al. (Cancer Res. 53, 4164-4167, 1993) found no evidence of resistance in fibroblasts derived from p53 null mice. The aim of our study was to compare the radiation response of hemopoietic colony-forming cells (in vitro CFC) and of fibroblastoid colony-forming cells or units (CFU-F) within the same tissue (marrow) in p53 null mice (-/-), heterozygotes (+/-) and wild-type animals (+/+). We have also tested the hypothesis that, in proliferating cells, radiation-induced cell killing is mediated through chromosome damage by examining the relationship between these end points in hemopoietic cells of the three mouse types. Both in vitro CFC and CFU-F of -/- mice were resistant to cell killing compared with +/+ and +/- mice whose cellular sensitivities were indistinguishable. The resistance was characterized by a broader "shoulder" on the cell survival curve, i.e. a higher extrapolation number but similar D0 values using the multitarget model or a lower alpha coefficient using the linear-quadratic model. The frequency of chromosomally abnormal marrow cells after irradiation was similar for the three genotypes. However, marrow cells with aberrations carried more aberrations in -/- mice than in +/+ or +/- mice such that the total number of aberrations per 100 cells was higher in -/- mice. Since there were no differences in the yields of aberrations between genotypes in spleen lymphocytes or in CFU-F (both noncycling at the time of irradiation) and less mitotic inhibition in -/- marrow cells than in +/+ or +/- cells, the chromosomal radiosensitivity of -/- marrow hemopoietic cells might be related to reduced cell cycle delay allowing insufficient time for repair, but other explanations have been considered. We postulate that the radiation resistance of both hemopoietic CFC and CFU-F in -/- mice is a consequence of the failure of DNA/chromosome damage to trigger apoptosis or permanent cell cycle arrest to the same extent as in the +/+ or +/- mice: hence the lack of correlation between chromosome damage and cell death in the three mouse types.

Analysis of Variance↗

BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.

The stem cell inhibitor, macrophage inflammatory protein-1 alpha (MIP-1 alpha) or LD78, protects multipotent hematopoietic progenitors in murine models from the cytotoxic effects of chemotherapy. Clinical use of human MIP-1 alpha during chemotherapy could therefore lead to faster hematologic recovery and may allow dose intensification. We have also shown that human MIP-1 alpha causes the rapid mobilization of hematopoietic cells, suggesting an additional clinical use in peripheral blood stem cell transplantation. However, the clinical evaluation of human MIP-1 alpha is complicated by its tendency to associate and form high molecular weight polymers. We have produced a variant of rhMIP-1 alpha, BB-10010, carrying a single amino acid substitution of Asp26 > Ala, with a reduced tendency to form large polymers at physiologic pH and ionic strength. This greatly increases its solubility, facilitating its production and clinical formulation. We confirmed the potency of BB-10010 as a human MIP-1 alpha-like agonist in receptor binding, calcium mobilization, inhibition of colony formation, and thymidine suicide assays. The myeloprotective activity of BB-10010 was shown in a murine model of repeated chemotherapy using hydroxyurea. BB-10010 is therefore an ideal variant with which to evaluate the therapeutic potential of recombinant human MIP-1 alpha.

Amino Acid Sequence↗

Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha.

BB-10010 is a genetically engineered variant of human macrophage inflammatory protein-1 alpha with improved solution properties. We show here that it mobilizes stem cells into the peripheral blood. We investigated the mobilizing effects of BB-10010 on the numbers of circulating 8-day spleen colony-forming units (CFU-S8), CFU-S12, and progenitors with marrow repopulating ability (MRA). A single subcutaneous dose of BB-10010 caused a twofold increase in circulating numbers of CFU-S8, CFU-S12, and MRA 30 minutes after dosing. We also investigated the effects of granulocyte colony-stimulating factor (G-CSF) and the combination of G-CSF with BB-10010 on progenitor mobilization. Two days of G-CSF treatment increased circulating CFU-S8, CFU-S12, and MRA progenitors by 25.7-, 19.8-, and 27.7-fold. A single administration of BB-10010 after 2 days of G-CSF treatment increased circulating CFU-S8, CFU-S12, and MRA even further to 38-, 33-, and 100-fold. Splenectomy resulted in increased circulating progenitor numbers but did not change the pattern of mobilization. Two days of treatment with G-CSF then increased circulating CFU-S8, CFU-S12, and MRA by 64-, 69-, and 32-fold. A single BB-10010 administration after G-CSF treatment further increased them to 85-, 117-, and 140-fold, respectively, compared with control. We conclude that BB-10010 causes a rapid increase in the number of circulating hematopoietic progenitors and further enhances the numbers induced by pretreatment with G-CSF. BB-10010 preferentially mobilized the more primitive progenitors with marrow repopulating activity, releasing four times the number achieved with G-CSF alone. Translated into a clinical setting, this improvement in progenitor cell mobilization may enhance the efficiency of harvest and the quality of grafts for peripheral blood stem cell transplantation.

Animals↗

Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors.

The effects of epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha), insulin-like growth factor (IGF) I and II, acidic fibroblast growth factor (FGF), tumour necrosis factor alpha (TNF alpha), macrophage inhibitory protein 1 alpha (MIP-1 alpha) (LD78), and TGF beta-1 on cell proliferation in the crypts of the small intestine of mice were investigated. Various doses and dosing regimens were tested. Three in vivo assays were developed, in each case involving detailed cell positional analysis of methyl tritiated thymidine labelling and mitotic activity. These allowed deductions to be made about the regions of the crypt and hence regions of the proliferative hierarchy (stem cells versus dividing transit cells) that are affected by treatment with growth factors. The assays involved: (1) normal untreated mice (an assay most likely to be effective for detecting inhibitors); (2) mice shortly after whole body irradiation when compensatory proliferation has been endogenously triggered (another assay for inhibitory factors, possibly ones associated specifically with the regenerative process); and (3) mice at late times (96 hours) after irradiation in the regression phase after a proliferative overshoot (an assay designed to detect stimulators). Little effect was seen after treatment with acidic FGF, TNF alpha, or MIP-1 alpha but EGF, IGF-I and II, and TGF alpha can all be seen to exert some stimulatory effects on labelling or mitosis. EGF and IGF-I stimulate both unirradiated mice and 96 hour recipients, while TGF alpha had a greater effect on the 96 hour animals. In all cases, multiple doses were used. TGF beta-1 was an effective inhibitor of proliferation in unirradiated and early regenerating (18 hour) animals. EGF was the most effective of the stimulators, raising the levels of proliferation at all positions in the crypt, but particularly in the upper crypt. IGF-I also exerted its effect predominantly in the upper crypt, while TGF alpha raised proliferation at all cell positions. TGF beta-1 tended to have its strongest inhibitory effects in the lower (stem cell) regions of the crypt.

Animals↗

MIP-1 alpha increases the self-renewal capacity of the hemopoietic spleen-colony-forming cells following hydroxyurea treatment in vivo.

In this report, the effect of macrophage inflammatory protein (MIP-1alpha) on the self-renewal, in vivo, of haemopoietic spleen colony-forming units (CFU-S) following cytotoxic damage, has been investigated. CFU-S recovery following injection of hydroxyurea, HU (1 g/kg at 0 and 7 hers) with or without MIP-1alpha intervention was measured over the following 5 days. In addition to the initial protection conferred by MIP-1alpha, the CFU-S population recovered about 1.7 times faster than in the unprotected controls. Direct measurement of the self-renewal capacity of the CFU-S population was made at 2 days after HU + MIP-1alpha treatment by measuring the number of CFU-S/spleen colony in a secondary transplant assay. CFU-S following HU treatment alone generated 60 CFU-S/colony. Additional MIP-1alpha treatment increased this to 90 CFU-S/colony. It is concluded that MIP-1alpha modifies the generation age structure of a regenerating CFU-S population such that recovery is initiated from the more primitive cells of the population's age spectrum and that this observation should extend the range of cytotoxic agents from which MIP-1alpha can give protection.

Animals↗

Gamma irradiation of the fetus damages the developing hemopoietic microenvironment rather than the hemopoietic progenitor cells.

Hemopoiesis is the product of two components: the hemopoietic tissue and the regulatory stromal microenvironment in which it resides. Plutonium-239, incorporated during fetal development, is known to cause deficient hemopoiesis. A predetermined equivalent gamma-ray dose has now been used in combination with cross-transplantation experiments to separate these two components and define where the damage arises. It was confirmed that 1.8 Gy gamma irradiation at midterm gestation caused a 40% reduction in the hemopoietic stem (spleen colony-forming) cell population of their offspring which persisted to at least 24 weeks of age. Spleen colony formation after sublethal doses of gamma rays reflected this reduced complement of endogenous stem cells. The regulatory hemopoietic microenvironment, measured as fibroblastoid colony-forming cells, was similarly depleted. Normal growth of the CFU-S population after transplantation into standard recipients showed that the quality of the stem cell population in the offspring of irradiated mothers was not affected. By contrast, when used as recipients of a bone marrow transplant from either normal or irradiated offspring, the offspring of irradiated mothers were unable to support normal growth: there was a twofold difference in the number of CFU-S per femur for at least 100 days after transplantation. There were 70% fewer CFU-F in the femur 1 month after bone marrow transplantation when the offspring of irradiated mothers were used as transplant recipients compared to when normal offspring were used. This not only confirmed their reduced capacity to host normal stem cells but also indicated that CFU-F in the transplant were unable to compensate for the poor microenvironment in the irradiated offspring hosts. It is concluded that irradiation at midterm gestation damages the developing regulatory microenvironment but not the hemopoietic stem cell population that it hosts.

Animals↗

Apoptosis in bone marrow cells of mice with different p53 genotypes after gamma-rays irradiation in vitro.

Apoptosis is a physiological phenomenon occurring during embryonic development, T and B cell maturation, and endocrine-induced atrophy. It can be initiated by various agents and has been considered to be related to the expression of the oncosuppressor p53 gene. In this review, p53 gene-targeting mice were used to study the effect of p53 gene status on the induction of apoptosis in bone marrow cells by gamma-ray irradiation. The results showed that homozygous null (p53 -/-) murine bone marrow cells were more resistant to the induction of apoptosis by radiation than other genotypes (heterozygous, p53 +/- and wild type, p53 +/+). The percentage of apoptotic cells in p53 +/+ mice was about three times that in p53 -/- mice at 4 hr after 6 Gy gamma-irradiation, and the analysis of the apoptosis-characteristic DNA ladder further supported these findings. We found that the homozygous null mice also can undergo apoptosis after irradiation. This suggested that there is another independent apoptotic p53 gene mechanism in irradiated murine bone marrow cells. Thus, in murine bone marrow cells, both p53 gene-dependent and -independent apoptosis occurred after irradiation. In our previous work, an increase in survival of hemopoietic progenitor cells after irradiation in vitro in p53 gene deletion mice was observed. This increase is closely related to the inhibition of apoptosis in bone marrow cells in p53 gene deletion mice.

Animals↗

Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination.

Patients with advanced adenocarcinoma of the colon, rectum or pancreas were entered into trials for evaluation of treatment with sequential doses of IL-3 and GM-CSF. They received 0.25 to 5 micrograms IL-3/kg/d for up to 7 days, followed by 1 microgram GM-CSF/kg/day for a maximum of 10 further days. We assessed the kinetics of bone-marrow cell proliferation and of blood production using tritiated thymidine labelling in vitro and in vivo. Megakaryocytic-CFC were unaffected but proliferation rates of GM-CFC and BFU-E were increased. Progenitor cells were mobilized (12-fold over baseline) into the peripheral blood. The proliferative activity of maturing cells in the marrow was increased (cell-cycle times were reduced by at least 30%). This translated into amplified blood cell production (WCC approximately 30 x 10(9)/l), a 2.2-fold increase in platelet counts and significant eosinophilia. Newly generated neutrophils appeared in the circulation at the normal time and their peripheral half-life was also normal. The calculated 3.2-fold amplification in neutrophil production required nearly 2 extra divisions in the marrow, shared between the progenitors and the proliferating granulocytic cells. The results were compared with those of a previous trial using GM-CSF only, although at a 10-fold higher dose level. Comparable levels of peripheral neutrophils were obtained in both trials but significant ineffective granulopoiesis developed in the earlier study. This was overcome in the present study, the priming dose of IL-3 apparently giving the latitude to utilize lower doses of GM-CSF with less risk of complications.

Adenocarcinoma↗

Alpha particles are extremely damaging to developing hemopoiesis compared to gamma irradiation.

Estimates of risk of stochastic effects from contamination with alpha-particle-emitting radionuclides are based on equivalent doses which take into account the RBE of the high-LET radiation. ICRP has recommended a dose-weighting factor, wR, of 20 for alpha-particle radiation. It is assumed that the RBEs for deterministic effects are considerably less than those for stochastic effects. However, the offspring of mice injected with 30 Bq g-1 239Pu at 13 days gestation develop a persistent deficit in hemopoietic stem cells which is primarily the result of damage to their regulatory microenvironment. Their spatial distribution in the marrow is also perturbed, and recent observations on those mice suggested a considerably higher factor than 20. To define a more realistic RBE for hemopoiesis, the effects of external gamma irradiation during the fetal development period have been compared directly with those of 239Pu incorporated via placental transfer on the development of hemopoietic tissue. Pregnant mice were irradiated with 60Co gamma rays (a) continuously from day 13 of gestation to birth at 0.15 or 0.6 Gy/day; (b) six repeated acute doses (0.6 Gy/min) at 0.1 or 0.3 Gy from day 13 of gestation; (c) one acute dose of 0.6 or 1.8 Gy on day 15 of gestation. The spatial distribution of hemopoietic stem cells in 8-week-old offspring was then determined and compared to that resulting from alpha-particle irradiation. In each case, the higher dose was required to match the results for alpha particles, suggesting an RBE for developing hemopoiesis of 250-360 compared to a continuous gamma-ray dose and a rather lower value of 130-180 compared to a single acute dose of gamma rays. This contrasts greatly to values for direct irradiation of the stem cells but argues that the effective RBE, measured for long-term effects in vivo, is the more realistic. It is concluded that an all-embracing factor can be grossly misleading in the specification of protection guidelines and can greatly underestimate the risks of exposure to alpha particles.

Alpha Particles↗

Proliferation of spleen colony forming units (CFU-S8, CFU-S13) and cells with marrow repopulating ability.

The practicalities of gene transfer therapy using retroviral vector systems require both that host cells be as primitive as possible and that those cells be proliferating. Here, the kinetics of hemopoietic stem cells with marrow repopulating ability (MRA) have been studied with a view to defining the timescale over which these normally quiescent cells can be triggered into cell cycle. Mice were injected with hydroxyurea (1 g/kg) four times over a period of 26 h and assayed at intervals up to eight days for 8-day and 13-day spleen colony-forming units (CFU-S) and for generation of 12-day CFU-S in the bone marrow (MRA assay). The proliferative activity of these cell populations was measured by in vitro tritiated thymidine assays. CFU-S were reduced rapidly to 11% of normal and induced into cycle. Their number and proliferative quiescence recovered by four to five days. Cells with MRA reached their nadir after four days and only then started to proliferate. For each of these progenitor cell subclasses, the proliferative activity inversely reflects their numbers and indicates regulation by negative feedback processes.

Animals↗

Stimulator of proliferation of spleen colony-forming cells in acute sterile inflammation.

The presence and activity of a spleen colony-forming cell (CFU-S) proliferation stimulator was investigated in rat bone marrow after induction of sterile inflammation. Wistar rats were treated intraperitoneally with two 15 ml injections of 3.5% polyvinylpyrrolidone (PVP) at 18 h intervals, and the presence of CFU-S proliferation stimulator determined in bone marrow 6, 20 and 24 h after the first injection. The marrow of these mice was used to condition medium which was then fractionated using Amicon Diaflo ultrafiltration membranes. The 30-50 kDa fraction, taken from 20h post-PVP-bone marrow extract, was found to induce cycling of d8-CFU-S in normal mouse bone marrow. This activity was not related to the presence of interleukins-1, -2 or -6 like activities in the material tested. The results demonstrate the existence of CFU-S proliferation stimulator in the bone marrow of rats with sterile inflammation (i.e. in an in vivo tissue response to non-specific cell stimulation), similar to that originally described as a macrophage product in mouse bone marrow after treatment with a variety of cytotoxic agents.

Animals↗

A relationship between residual stromal damage in hematopoietic tissue and the functional activity of granulocytes.

This paper analyzes the function of mouse granulocytes in the long term, after external irradiation with x- and gamma-rays and 239Pu contamination at different gestational ages and in a variety of culture conditions. These treatments can produce persistent defects in the stroma, which regulates hematopoiesis. Superoxide-anion production has been measured in granulocytes from peripheral blood and from long-term bone marrow cultures (LTBMC). A significant enhancement of O2- is produced using single or fractionated doses of x-rays; however, little or no increase is observed with gamma-rays. With 239Pu, enhancement of O2- depends on gestational age at contamination. The absence of hydrocortisone (HC) in LTBMC and the irradiation of the adherent layer with 15 Gy stimulate O2- production. The increased production of O2- appears to be correlated with an excess of colony-stimulating factors (CSFs) released to the supernatant by stromal cells. Neutralization with anti-granulocyte-macrophage CSF (anti-GM-CSF) monoclonal antibody shows that GM-CSF is the main factor produced. In summary, conditions that lead to residual stromal damage also result in the generation of granulocytes that are functionally primed for excess superoxide-anion production.

Animals↗